Emergent BioSolutions Inc
NYSE:EBS

Watchlist Manager
Emergent BioSolutions Inc Logo
Emergent BioSolutions Inc
NYSE:EBS
Watchlist
Price: 13.43 USD 4.51%
Market Cap: 705.3m USD

Emergent BioSolutions Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Emergent BioSolutions Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Emergent BioSolutions Inc
NYSE:EBS
Net Income (Common)
$75.9m
CAGR 3-Years
12%
CAGR 5-Years
-15%
CAGR 10-Years
2%
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$2.3B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$8.1B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

Emergent BioSolutions Inc
Glance View

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,416 full-time employees. The company went IPO on 2006-11-15. The firm is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. The company provides solutions for public health threats through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The firm also offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers.

EBS Intrinsic Value
22.77 USD
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Emergent BioSolutions Inc's Net Income (Common)?
Net Income (Common)
75.9m USD

Based on the financial report for Sep 30, 2025, Emergent BioSolutions Inc's Net Income (Common) amounts to 75.9m USD.

What is Emergent BioSolutions Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
2%

The average annual Net Income (Common) growth rates for Emergent BioSolutions Inc have been 12% over the past three years , -15% over the past five years , and 2% over the past ten years .

Back to Top